Full-Time

Automation Projects Engineer

Updated on 7/3/2025

Viatris

Viatris

10,001+ employees

Global pharmaceutical company providing medicines

No salary listed

Mid, Senior

Minna, Inverin, Co. Galway, Ireland

In Person

Category
Process Engineering
Required Skills
Python
SQL
C#
VBA
Data Analysis
Requirements
  • Bachelor’s or Master’s degree in Automation, Mechanical, Electrical, Industrial Engineering, or a related field
  • 3–5 years of hands-on experience in automation within the pharmaceutical, biotech, or life sciences industry
  • Professional certifications such as GAMP 5 Practitioner, Certified Automation Professional (CAP), Six Sigma, Lean Manufacturing, or PMP (Project Management Professional)
  • Proficiency in PLC programming (e.g., Siemens, Allen-Bradley, Schneider) and automation control systems
  • Experience with SCADA and DCS platforms (e.g., Wonderware, DeltaV, Siemens PCS7, Rockwell)
  • Knowledge of MES systems such as Werum PAS-X or Rockwell PharmaSuite
  • Skilled in industrial communication protocols including OPC, Modbus, Profibus, and Ethernet/IP
  • Familiarity with robotic automation, machine vision systems, and industrial data analytics tools
  • Basic programming or scripting skills in Python, SQL, VBA, or C# for automation and data integration tasks
Responsibilities
  • Develop, configure, and deploy PLC, SCADA, DCS, MES, and HMI automation systems.
  • Implement process control strategies to optimize manufacturing and laboratory operations.
  • Collaborate with cross-functional teams (Engineering, IT, Quality, Production) to integrate automation solutions.
  • Provide technical support for automation-related issues, minimizing downtime.
  • Conduct root cause analysis (RCA) and implement corrective actions for system failures.
  • Ensure systems are validated, calibrated, and maintained according to regulatory requirements.
  • Ensure adherence to cGMP, FDA 21 CFR Part 11, GAMP 5, EU Annex 11, and other regulatory standards.
  • Develop and maintain technical documentation, including URS, FDS, HDS, SDS, IQ/OQ/PQ protocols.
  • Participate in regulatory audits and inspections, providing automation-related compliance support.
  • Drive process automation enhancements to improve manufacturing efficiency and reduce operational costs.
  • Stay updated on emerging technologies in Industry 4.0, IoT, data analytics, AI-driven automation.
  • Support digital transformation initiatives such as cloud-based automation and electronic batch records (EBR).

Viatris provides access to a wide range of medicines through its diverse portfolio, which includes branded and generic drugs, complex generics, and biosimilars. The company operates by utilizing its global commercial infrastructure and supply chain to ensure high-quality medicines reach patients in over 165 countries. Viatris generates revenue from the sale of its pharmaceutical products, focusing on key therapeutic areas such as cardiovascular health, infectious diseases, immunology, and oncology. What sets Viatris apart from its competitors is its commitment to addressing public health challenges, particularly the increasing prevalence of non-communicable diseases, and its strategy of both organic growth through its existing products and inorganic growth through partnerships and acquisitions. The goal of Viatris is to improve patient health and provide sustainable access to essential medicines.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris benefits from the growing biosimilars market, projected to grow at 24.7% CAGR.
  • The Asia-Pacific pharmaceutical market's growth offers expansion opportunities for Viatris.
  • Increased demand for cardiovascular drugs aligns with Viatris's key therapeutic areas.

What critics are saying

  • Increased competition in biosimilars could impact Viatris's market share and pricing power.
  • Patent litigation may lead to financial liabilities or loss of market exclusivity.
  • Viatris's significant debt load could limit financial flexibility and growth investments.

What makes Viatris unique

  • Viatris combines generics and branded drugs to address global healthcare needs holistically.
  • The company leverages a unique global supply chain to deliver medicines to 165 countries.
  • Viatris's diverse portfolio includes branded drugs, generics, complex generics, and biosimilars.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

The Indian Express
Jun 24th, 2025
Biocon's $3.3B Viatris Acquisition Impact

Biocon's acquisition of Viatris for $3.3 billion marks a potential turning point for the company, which has seen muted growth. Despite revenue growth, concerns about debt, equity dilution, and valuation persist. Biocon's business now includes biosimilars, contract research, and generics. The company plans to raise ₹4,500 crore through a Qualified Institutional Placement to reduce its ₹17,756 crore debt. A potential merger with Biocon Biologics Ltd could unlock further value.

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally